The assesssment of efficacy and safety of Irreversible Electroporation (IRE) for patients with hepatocellular carcinoma (HCC)

The assesssment of efficacy and safety of Irreversible Electroporation (IRE) for patients with hepatocellular carcinoma (HCC) - IRE therapy for patients with HCC

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013732

Enrollment

Registered

2014-04-16

Start date

2014-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellualr carcinoma

Interventions

Irreversible Electroporation(IRE)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Liver function: Child A, B 2. WBC>2000 3. Plt>50000 4. Cr<3.0 5. Normal ECG 6. PS: 0, 1 7. Survival time>4 weeks 8. Tumor size and number: less than or equal 3cm and 3 or less than or equal 5cm and solitary

Exclusion criteria

Exclusion criteria: 1. Patients with other malignancy 2. Pregnancy case 3. Patients with severe heart brain disease

Design outcomes

Primary

Measure	Time frame
the effect and usefulness of therapy	—

Secondary

Measure	Time frame
the safety	—

Countries

Japan

Contacts

Public ContactKatsutoshi Sugimoto

Tokyo Medical University Gastroenterology and Hepatology

sugimoto@tokyo-med.ac.jp03-3342-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026